The Influence of Micronutrition on Survival and

Quality of Life When Combined with Standard

Therapy Protocols for Aggressive and Advanced

Malignancies 

H. R. McDaniel, M.D. Medical Director, Fisher Institute for Medical Research, Grand Prairie, Texas 

In 1985 pilot studies using the bioactive extract from aloe leaf gel, polymannose (APM) was used in AIDS patients.  Elevations of CD4 lymphocytes and reductions in HIV-1 viral load was noted (McDaniel 1988) in parallel with remissions of Kaposis sarcoma and lymphoma tumor mass.  This led to adding APM to the diet of advanced and hospice cancer patients that had failed standard treatment protocols.  Tumor mass reduction and increase in quality of life was noted in 40 to 50% of patients (McDaniel 1990).  The working hypothesis was that innate immune mechanisms that counter viral infections that integrate nucleic acid sequences into the genome have similar activity to detect and destroy cells with oncogene mutations.   It was recognized that 9 molecules of manose-6POrequired in the endoplasmic reticulum (Kornfeld 1985) to start synthesis of antiviral and anti-malignant cell cytokines. Michaelis-Menten substrate supply dynamics predict that synthesis of cytokines will be increased if the APM supply is increased (Murray 1990).  In mixed-leukocyte cultures a dose-response gradient by ELISA assay for increased synthesis of γ-interferon, IL-1, IL-2, IL-6, and TNF was noted (Marshall 1993).  A 4-hour incubation of cells from the previous experiment (NK assay) demonstrated a rising lysis gradient released by Cr 59 laden target malignant cells and herpes II-seeded cells that was proportional to the supply of APM provided leukocytes (Marshall 1993).  Murine sarcoma 100% resistant to therapeutic modalities responded to a single APM injection by a 40% eradication of tumor cells.  Bi-weekly administration raised survival to 65% and combined with surgical removal survival rose to 85-90% (Busbee 1996). A report of 100 miscellaneous anecdotal cases of various types of malignancy in which micronutrients were provided with standard protocols claimed an increase in quality of life during treatment, enhanced tumor mass reduction, protection of bone marrow and stem cells and responses in cell types resistant to standard therapy (Hyland 1999). 

The current report is a case series survey of human malignancies associated with short survivals that combined micronutrient dietary supplementation with standard therapy for malignancies.   It is prepared for a “Best Case Series” Center for Complementary and Alternative Medicine cooperative NCI grant.   For review will be 6 cases of pancreatic cancer with metastasis that have an average survival of 82 months survival with a range of (48 -140_months with 3 living; 4 astrocytoma Grade III-IV average survival of 73 months, ranging (20-117) with two living; 5 sarcomas averaging 94months survival ranging 87-131 with 5 living; miscellaneous advanced recurrent malignancies with initial hospice status with an average survival of 178 months ranging (94-263) months survival.   While undergoing standard radiation or chemo therapy there was a significant improvement in quality of life as indicated by less fatigue, nausea, vomiting, bone marrow toxicity, mucositis, loss of appetite, weight loss, and hair loss.  It is concluded that formal prospective studies with and without micronutrient dietary supplementation combined with standard treatment protocols for a comparison of quality of life, tumor mass impact, and survival is warranted.  
 
 

More details including patient scans can be obtained in the Best Case Cancer Syllabus available at Fisher Institute    Helen@fisherinstitute.org or (972) 660-1733 

An alternative is the two DVDs on cancer availavle duplipack@aol.com  888-443-1979

 

Interview Work Sheet for Best Case Series:       Diagnostic Group________________

Patient Name_____________________

Date of Birth__________

Contact information_________________ 

Permission to obtain records received_____

App. Date of first symptoms that led to discovering malignancy_____________ 

Date diagnosis of malignancy was made_____________

      How was diagnosis established

      Where and who did the procedure_______________

Treatments received:

      Date and place of surgery_______________________ _____________________ 

      Tumor said to be completely removed______________________ 

      Date of reocurrance_______________

            How determined___________

            Where__________

            Tumor metastatic to Lungs__, liver_, brain__, bone__, other___________ 

Additional treatment_____________________ _________________________ 

Date Micronutrients started:_______  Standard treatment Chemo___Radiation___

                                     Other______

Products and       maximum about used/day  
Ambrotose bulk _______    _________

Phytaloe bulk _________    _________ 
PLUS______      _________

Sport______ pain benefits?____   _________

Catalyst_______     _________

Glyesentials____     _________

Other natural products?___________

                  ____________

                  ____________ 

Did you have previous treatment without micronutrients?___

Did you have treatment with Micronutrients?____________

Was there a difference?___   Explain difference Any tumor now detected___ 
Nausea__vomiting  appetite  mucositis  anemia   platelets  white count wt. loss 

Fatigue  endurance 

Weight before tumor ____  lowest wt_____.   current weight____  

Current Status?  This date______  Years since diagnosis___

All evidence of tumor gone? ____ Tumor markers normal? Percent of quality of life for age____?  Working?___

                                                                           
Use back for other comments: